Considering the aforementioned roles of ANXA10, it is possible that the upregulation of ANXA10 in duodenal adenomas indicates a protective “gastric programming.” Downregulation during the transition from FAP control to FAP case adenoma and from FAP case adenoma to cancer may reflect a loss in the tumor suppressive function of ANXA10. Given these findings, determining tissue expression of ANXA10 may predict the likelihood that a duodenal adenoma progresses to cancer in FAP. The gene discussed is ANXA10; the disease is cancer.